• Molecular NameZiprasidone
  • SynonymZiprasidone hydrochloride; Ziprasidone mesylate trihydrate
  • Weight412.945
  • Drugbank_IDDB00246
  • ACS_NO146939-27-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.03
  • pkaN/A
  • LogD (pH=7, predicted)3.66
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.23
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA76.71
  • StatusFDA approved
  • AdministrationOral, intramuscular
  • PharmacologyThe fifth atypical antipsychotic to gain FDA approval (February 2001).
  • Absorption_value60.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability60.0
  • Protein binding99.9
  • Volume of distribution (VD)2.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmApproximately one third of the dose is oxidized by CYP3A4, and the remainder undergoes reduction (aldehyde reductase).
  • Half life2.9 h (A longer t1/2 after oral dosing is rate-limited by absorption; food decreases apparent t1/2. In the elderly, the t1/2 is slightly longer)
  • ExcretionUrine and feces
  • Urinary Excretion<1
  • Clerance11.7 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A